LYRA Lyra Therapeutics
- 0.255
- +0.006+2.20%
Lyra Therapeutics News
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Palasis Maria
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Cavalier Jason
Lyra Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(19.5%),Joseph Edelman(19.5%), etc.
Lyra Therapeutics | 10-Q: Q2 2024 Earnings Report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics | 8-K: Current report
Lyra Therapeutics | 8-K: Current report
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ALTMAN MICHAEL SETH
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Poukalov Konstantin
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director TOBIN JAMES R
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director snyderman nancy lynn MD
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Smith W Bradford
Lyra Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director MERRIFIELD C ANN
Lyra Therapeutics | 8-K/A: Current report (Amendment)
Lyra Therapeutics | 8-K: Current report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics | 10-Q: Q1 2024 Earnings Report
Lyra Therapeutics | DEFA14A: Others
Lyra Therapeutics | DEF 14A: Definitive information statements
Lyra Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Analysis
Price Target
No Data
No Data